Programmed Cell Death Protein 1 Inhibitors and MET Targeted Therapies in NSCLC With MET Exon 14 Skipping Mutations: Efficacy and Toxicity as Sequential Therapies.
Lau SCM, Perdrizet K, Fung AS, Mata DGMM, Weiss J, Holzapfel N, Liu G, Bradbury PA, Shepherd FA, Sacher AG, Feilotter H, Sheffield B, Hwang D, Tsao MS, Cheng S, Cheema P, Leighl NB.
Lau SCM, et al. Among authors: holzapfel n.
JTO Clin Res Rep. 2023 Aug 19;4(10):100562. doi: 10.1016/j.jtocrr.2023.100562. eCollection 2023 Oct.
JTO Clin Res Rep. 2023.
PMID: 37744308
Free PMC article.